Dow Up0.19% Nasdaq Up0.56%

Sunesis Pharmaceuticals, Inc. (SNSS)

-NasdaqCM
2.07 0.06(2.82%) Nov 20, 4:00PM EST
ProfileGet Profile for:
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States - Map
Phone: 650-266-3500
Fax: 650-266-3501
Website: http://www.sunesis.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:32

Business Summary 

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company’s lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AMl. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of PDK1. The company was founded in 1998 and is headquartered in South San Francisco, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Sunesis Pharmaceuticals, Inc.

Corporate Governance 
Sunesis Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 6; Compensation: 4.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Daniel N. Swisher Jr., 51
Chief Exec. Officer, Pres and Director
734.00K62.00K
Mr. Eric H. Bjerkholt , 54
Chief Financial Officer, Principal Accounting Officer, Exec. VP of Corp. Devel. & Fin. and Corp. Sec.
534.00K0.00
Dr. Adam R. Craig M.D., Ph.D., M.B.A., 48
Chief Medical Officer and Exec. VP of Devel.
575.00K0.00
Mr. Gene C. Jamieson ,
VP of Technical Operations
N/AN/A
Mr. Joseph I. DePinto , 47
Chief Commercial Officer and Exec. VP
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders